Guanchi Bio Group

Guanchi Bio Group, based in China, specializes in innovative biotechnological solutions aimed at improving health outcomes through advanced stem cell and immune cell therapies. Founded in 2015, Guanchi Bio Group operates in Guangzhou, China, focusing on the development and provision of stem cell and immune cell services. The company has successfully secured CNY 40 million in Series A funding led by Fuxing Capital, with participation from Early Traveler Venture Capital and Chuangfu Investment. This funding round marks their sole notable deal to date, completed on June 18, 2025.

Guangdong Guanchi Stem Cell Medical Technology Co. , Ltd. specializes in advanced biotechnological solutions aimed at addressing various health issues, including suboptimal health conditions, anti-aging, chronic diseases, and tumors. The company's core product offerings include mesenchymal stem cells, autologous NK immune cells, immune cell storage, and adipose-derived stem cells.

These products leverage research and development in stem cell technology, immune cell applications, and cell storage techniques, primarily targeting the healthcare sector in China. Guangdong Guanchi Stem Cell Medical Technology Co. , Ltd. generates revenue through specialized stem cell and immune cell services involving transactions with healthcare providers and individual consumers.

Their business model includes direct-to-consumer sales and partnerships with medical facilities, primarily based on service fees associated with stem cell collection, storage, and therapeutic applications. The company's offerings are positioned as premium solutions within the healthcare market. In June 2025, Guanchi Bio Group raised CNY 40 million in Series A funding to support the development of new regenerative therapies and expand their market reach. The company plans to introduce new products targeting various health conditions, aiming for a market entry in additional regions of China and potentially beyond by late 2025.

The recent funding will be utilized to enhance research and development efforts, ensuring that they remain at the forefront of biotechnological advancements.